BioPharmSignal logoBioPharmSignal

Biotech News

Gyre Therapeutics to Participate in Upcoming September Investor Conferences

Catalyst Biosciences (CBIO)Catalyst BiosciencesCommercial

SAN DIEGO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (Gyre, Gyre Therapeutics or the Company) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company with operations in the United States and China, today announced that Company management will participate in the

Related news

CBIOCatalyst Biosciences2026-07-16 20:05 EST

Gyre Therapeutics Appoints Three New Members to its Board of Directors

CBIOCatalyst Biosciences2026-05-12 20:06 EST

Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment

View all latest news

Catalyst Biosciences

Catalyst Biosciences was a biotechnology company focused on engineered proteins for hemostasis, complement, and related inflammatory biology before becoming a historical ticker. Its story was built around protein-engineering approaches to difficult disease pathways.

Recent company news

CBIOCatalyst Biosciences2026-09-03 11:00 EST

Gyre Therapeutics to Participate in Upcoming September Investor Conferences

CBIOCatalyst Biosciences2026-08-07 11:00 EST

Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update

CBIOCatalyst Biosciences2026-07-16 20:05 EST

Gyre Therapeutics Appoints Three New Members to its Board of Directors

CBIOCatalyst Biosciences2026-05-12 20:06 EST

Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment

CBIOCatalyst Biosciences2026-05-07 10:00 EST

Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update

Stock data

Close
13.14 USD
Market cap
468.91M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States